Electromed, Inc. Form 10-Q Summary
Reporting period: The filing is for the quarter and nine months ended March 31, 2016, Electromed’s fiscal 2016 third quarter. The request metadata identifies “2015 Q3,” but the filing itself clearly reports 2016 results. Financial statements are unaudited.
Business Context
Electromed develops, manufactures and markets airway-clearance products using High Frequency Chest Wall Oscillation technology, principally the SmartVest Airway Clearance System. Products are sold in U.S. home-care and institutional markets and internationally through direct sales and distributors.
Key Financial Metrics
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net revenue | $6.04 million, up 32.5% | $17.30 million, up 21.7% |
| Gross profit | $4.63 million; 76.7% margin | $13.39 million; 77.4% margin |
| Operating income | $0.74 million | $2.57 million |
| Net income | $0.47 million, versus $0.04 million | $1.88 million, versus $0.84 million |
| Diluted earnings per share | $0.06, versus approximately $0.00 | $0.23, versus $0.10 |
| Operating cash flow | Not provided for the quarter | $1.67 million, versus $1.83 million |
Revenue growth was led by home-care revenue, which increased 37.6% for the quarter and 23.6% for the nine-month period. Institutional revenue declined 12.5% for the quarter but increased 14.4% year to date. International revenue increased 49.1% for the quarter and declined 1.3% year to date.
Gross margins improved materially from 69.3% to 76.7% for the quarter and from 69.4% to 77.4% for the nine-month period. Management attributed the improvement to higher domestic home-care approval rates, higher average selling prices and lower SmartVest SQL manufacturing costs.
Liquidity, Debt and Balance Sheet
- Cash was $4.93 million at March 31, 2016, compared with $3.60 million at June 30, 2015.
- Working capital was approximately $12.3 million. Total current assets were $15.19 million and current liabilities were $2.89 million.
- Total debt was approximately $1.21 million, consisting primarily of a term loan; the balance was approximately $1.24 million at June 30, 2015.
- The company had no borrowings under its $2.5 million revolving credit line. The full $2.5 million was available at quarter end, subject to borrowing-base limitations.
- Net cash increased $1.34 million during the first nine months. Investing activities used $0.28 million, and financing activities used $0.05 million.
- The term loan bears interest at 5.0%, requires monthly payments of approximately $8,600 and has an approximately $1.09 million final payment due December 18, 2018.
- The company was in compliance with its debt covenants, including a minimum tangible net worth requirement of $10.125 million.
Material Changes Versus Prior Comparable Period
- Quarterly revenue increased $1.48 million, or 32.5%; nine-month revenue increased $3.09 million, or 21.7%.
- Quarterly operating income increased from $58,000 to $736,000, while nine-month operating income increased from $903,000 to $2.57 million.
- SG&A increased 26.0% for the quarter and 22.0% year to date, driven by higher payroll, commissions, bonuses, sales and reimbursement staffing, professional fees and travel.
- Research and development expense declined 22.8% year to date as major SmartVest SQL manufacturing-cost projects were substantially completed. Management expects R&D spending to increase over the next twelve months for product enhancements and other market opportunities.
- Operating cash flow declined modestly despite higher earnings, primarily because accounts receivable, inventory and income tax receivables increased.
- Income tax expense increased substantially because prior-year net operating loss carryforwards had offset taxable income. The company released its full valuation allowance against U.S. federal and state deferred tax assets, producing a discrete tax benefit of approximately $294,000 and reducing nine-month tax expense by approximately $288,000.
- A two-year moratorium on the medical-device excise tax beginning January 1, 2016 positively affected third-quarter operating profit.
Guidance, Outlook, Risks and Unusual Items
Management stated that existing working capital and available credit should provide adequate liquidity for the next year based on current operating performance. The company expects to fund planned equipment purchases with operating cash flow or credit-facility borrowings.
- Future results depend on continued growth in SmartVest SQL demand, reimbursement approvals, payer contracts and operating efficiencies.
- Home-care revenue benefited from approximately $250,000 of second-quarter revenue related to processing a backlog of referrals after the company obtained a required state home-medical-equipment license.
- International revenue may fluctuate significantly because of distributor purchase timing and international regulatory requirements.
- Key risks include competitive pressures, changes to Medicare, Medicaid and private-insurance reimbursement, healthcare-law changes, regulatory compliance and approvals, intellectual-property protection, and the ability to renew or replace the revolving credit facility after its December 18, 2016 expiration.
- Failure to comply with debt covenants could permit acceleration of borrowings, restrict access to credit or expose substantially all tangible and intangible assets and real property to lender remedies.
- The company records a $670,000 warranty reserve, reflecting lifetime U.S. patient warranties and three-year warranties for institutional and non-U.S. sales.
- No off-balance-sheet arrangements or material undisclosed litigation were reported.
Facts Investors Should Verify
- Whether the strong home-care growth and improved reimbursement approval rates are sustainable after the identified referral backlog benefit.
- The recurring versus discrete components of the effective tax rate, including the deferred-tax valuation-allowance release.
- Progress in institutional and international markets following the SmartVest SQL launch.
- Renewal of the $2.5 million revolving credit facility before December 18, 2016 and continued compliance with debt covenants.
- Accounts-receivable collection, inventory growth and the adequacy of the $670,000 warranty reserve.
- Whether higher SG&A investment and planned increases in research and development will support growth without materially reducing margins.